Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.550
-0.030 (-0.66%)
At close: Jun 26, 2026, 4:00 PM EDT
4.530
-0.020 (-0.44%)
After-hours: Jun 26, 2026, 4:17 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$798,576
Market Cap
5.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| NextCure | 40 |
| PMGC Holdings | 34 |
| Cardio Diagnostics Holdings | 17 |
| Soligenix | 14 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| CNS Pharmaceuticals | 8 |
APVO News
- 4 weeks ago - Aptevo Therapeutics appoints Janatpour as SVP, CSO - TheFly
- 4 weeks ago - Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D. - Accesswire
- 4 weeks ago - Aptevo, Niowave launch collab for radiopharmaceutical oncology programs - TheFly
- 4 weeks ago - Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Accesswire
- 6 weeks ago - Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M - TheFly
- 6 weeks ago - Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire
- 7 weeks ago - Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial - TheFly
- 7 weeks ago - Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire